Table 5.
Univariate and multivariate analyses of CR/CRi for patients with newly diagnosed AML.
| Covariates | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Agea | 0.433 (0.179-1.047) | 0.063 | ||
| Gender (male vs. female) | 1.266 (0.653-2.457) | 0.485 | ||
| WBCb | 0.863 (0.445-1.671) | 0.662 | ||
| Blasts in PBc | 0.118 (0.015-0.927) | 0.042 | 0.098 (0.012-0.800) | 0.030 |
| Blasts in BMd | 0.552 (0.056 -5.434) | 0.610 | ||
| Cytogeneticse | 0.306 (0.084-1.120) | 0.074 | ||
| Prognostic levelf | 0.334 (0.169-0.663) | 0.002 | 2.710 (1.199-6.123) | 0.017 |
| Bone marrow fibrosis | 0.008 | 0.001 | ||
| BMF-0 VS BMF-1 | 0.802 (0.336-1.916) | 0.619 | 0.906 (0.323-2.543) | 0.851 |
| BMF-0 VS BMF-2/3 | 0.344 (0.213-0.555) | 0.000 | 0.351 (0.194-0.634) | 0.001 |
| BMF-1 VS BMF-2/3 | 0.147 (0.057-0.383) | 0.000 | 0.189 (0.068-0.521) | 0.001 |
HR, hazard ratio; CI, confidence interval; aAge < 60 years old versus ≥ 60 years old; bWBC ≤10×109/L versus WBC >10×109/L; cBlasts in peripheral blood versus without blasts; dBlasts in bone marrow >20% versus = 20%; erisk versus intermediate and high risk; fLow and intermediate risk versus high risk. CR, complete remission; CRi, Morphologic complete remission with incomplete blood count recovery; AML, acute myeloid leukemia.